These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9872696)

  • 1. Cost and outcomes analysis of abciximab use in a community teaching hospital.
    Abernathy GB; Hewitt KK
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
    Anderson KM; Bala MV; Weisman HF
    Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 4. Murmurs from the heart (or why the stethoscope is not an economic tool).
    Aristides M; Gliksman M
    Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073
    [No Abstract]   [Full Text] [Related]  

  • 5. Enthusiasm, reality, and cost-effectiveness analysis.
    Brophy JM; Sleight P
    Heart; 1998 Jan; 79(1):9-10. PubMed ID: 9505910
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 7. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
    Boersma E
    J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
    [No Abstract]   [Full Text] [Related]  

  • 9. Elective or selective use of abciximab?
    Butler R; Samani NJ
    Lancet; 2000 Feb; 355(9205):755. PubMed ID: 10703832
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of eptifibatide and abciximab with decision analysis.
    Wong DH
    Am J Health Syst Pharm; 2001 Aug; 58(15):1432-6. PubMed ID: 11494790
    [No Abstract]   [Full Text] [Related]  

  • 12. Using cost-effectiveness for subsidy decisions.
    Glasziou P
    Heart; 1998 Jan; 79(1):7-8. PubMed ID: 9505908
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban.
    McCollam PL; Lage MJ; Bala M
    Catheter Cardiovasc Interv; 2001 Oct; 54(2):152-7. PubMed ID: 11590674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective.
    Zed PJ; Frighetto L; Sunderji R; Marra CA
    Ann Pharmacother; 1998 May; 32(5):536-42. PubMed ID: 9606473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of abciximab during coronary angioplasty].
    Philippe F; Montalescot G; Drobinski G; Thomas D
    Arch Mal Coeur Vaiss; 1997 Dec; 90(12):1645-50. PubMed ID: 9587446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital.
    Lucore CL; Trask RV; Mishkel GJ; Rocha-Singh KJ; Shelton ME; Mikell FL; Ligon RW
    Coron Artery Dis; 2001 Mar; 12(2):135-42. PubMed ID: 11281302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature].
    Sturm C
    Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients.
    Aristides M; Gliksman M; Rajan N; Davey P
    Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ; Foster RH
    Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.